Peptide News Digest

Novartis Pelacarsen Lp(a)HORIZON Phase 3 Miss, AstraZeneca Etcamah FDA Approval, Alteogen-Novartis $3.2B Hybrozyme

Novartis pelacarsen Phase 3 misses CV endpoint, AstraZeneca Etcamah wins US approval for ESR1 breast cancer, Alteogen-Novartis $3.2B Hybrozyme deal.

10 stories · Covering clinical-trials, regulatory, industry

Editor's Note

Friday's dominant story was a major setback for the Lp(a)-lowering cardiovascular hypothesis: Novartis's pelacarsen (partnered with Ionis and Royalty Pharma) missed the primary endpoint of the Phase 3 Lp(a)HORIZON trial for cardiovascular events in patients with elevated lipoprotein(a) and established cardiovascular disease, despite achieving the expected reductions in Lp(a) levels. The miss ends the leading test of whether Lp(a) is a directly-druggable causal risk factor and reshapes the commercial and clinical calculus for Amgen's olpasiran and Silence Therapeutics's zerlasiran, which are earlier in similar programs. Elsewhere on Friday: AstraZeneca's Etcamah (camizestrant, oral selective estrogen receptor degrader) was FDA-approved in combination with a CDK4/6 inhibitor for first-line hormone-receptor-positive advanced breast cancer patients with detected ESR1 mutations, with the Guardant360 CDx assay approved as companion diagnostic. Alteogen inked a $3.2 billion option and license agreement with Novartis for the ALT-B4 (berahyaluronidase alfa) subcutaneous-conversion platform, extending the same Hybrozyme technology approach that anchors Halozyme's earlier deals with Roche, Bristol Myers Squibb, and Johnson & Johnson. On the obesity pipeline: Superluminal Medicines raised $60 million Series B for a selective MC4R agonist for rare genetic obesity, and Chinese biotech QL Biopharm closed $73 million Series C to advance the monthly zovaglutide GLP-1 receptor agonist Phase 3 HORIZON-1 obesity program.

Clinical Trials

Novartis Pelacarsen Misses Primary Cardiovascular Endpoint in Phase 3 Lp(a)HORIZON Trial Despite Substantial Lp(a) Reduction; Reshapes Lp(a)-Targeting Landscape

Novartis (NYSE: NVS) announced Friday September 4, 2026 that the pelacarsen Phase 3 Lp(a)HORIZON trial did not meet its primary endpoint of reducing major adverse cardiovascular events (a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization) versus placebo in patients with elevated lipoprotein(a) plus established cardiovascular disease on guideline-directed background therapy including lipid-lowering and antihypertensive medications. Pelacarsen (an antisense oligonucleotide targeting hepatic APO(a) production, licensed from Ionis Pharmaceuticals in 2019) did achieve substantial lower Lp(a) levels versus placebo. The trial enrolled roughly 8,000 patients globally over 6 years and represents the largest and most consequential test to date of the Lp(a)-as-causal-cardiovascular-risk-factor hypothesis. The miss substantially raises the bar for Amgen's olpasiran (RNAi, Phase 3 OCEAN(a) ongoing), Silence Therapeutics's zerlasiran (RNAi), and Lilly's lepodisiran (RNAi) — all of which are testing similar Lp(a)-lowering-plus-cardiovascular-outcome frameworks. Ionis and Royalty Pharma both hold economic interests in pelacarsen.

#novartis #nvs #pelacarsen #lp-a-horizon #phase-3 #lp-a-lipoprotein-a #antisense-oligonucleotide #primary-endpoint-miss #8000-patients #ionis-partner #royalty-pharma #olpasiran-competitor #zerlasiran-competitor #lepodisiran-competitor #non-peptide
Regulatory

FDA Grants Accelerated Approval to AstraZeneca Etcamah (Camizestrant) Plus CDK4/6 Inhibitor for ESR1-Mutated HR+ HER2- Advanced Breast Cancer; Guardant360 CDx Approved as Companion Diagnostic

AstraZeneca (NASDAQ: AZN) announced Friday September 4, 2026 that the FDA granted accelerated approval to Etcamah (camizestrant, an oral selective estrogen receptor degrader) in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone-receptor-positive HER2-negative locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor plus CDK4/6 inhibitor therapy. FDA also approved the Guardant360 CDx blood-based next-generation sequencing assay as a companion diagnostic to identify ESR1-mutant patients. Approval was based on the Phase 3 SERENA-6 trial that documented a 56% reduction in disease progression or death versus continued standard-of-care aromatase inhibitor plus CDK4/6 inhibitor treatment in the ESR1-mutated subgroup. SERENA-6 was presented at ASCO 2026 and simultaneously published in the New England Journal of Medicine. Etcamah becomes the first oral SERD approved for the switch-at-emergence-of-ESR1 setting, replacing the fulvestrant intramuscular injection historically used post-progression. AstraZeneca is positioning Etcamah alongside Trodelvy plus Datroway as anchors of the expanded breast-cancer franchise.

#astrazeneca #azn #etcamah #camizestrant #oral-serd #cdk4-6-inhibitor #esr1-mutated #hr-positive-her2-negative #breast-cancer #guardant360-cdx #companion-diagnostic #serena-6 #56-percent-hazard-reduction #fulvestrant-successor #non-peptide
Industry

Alteogen and Novartis Sign $3.2 Billion Option and License Agreement for ALT-B4 (Berahyaluronidase Alfa) Subcutaneous-Conversion Platform

Alteogen (KOSDAQ: 196170) announced Wednesday September 2, 2026 an option and license agreement with Novartis (NYSE: NVS) for the development and commercialization of subcutaneous formulations of multiple Novartis products using Alteogen's ALT-B4 (berahyaluronidase alfa) enabled by the proprietary Hybrozyme technology. Terms: up to $3.22 billion in aggregate potential value including option exercise fees, development and commercial milestone payments, plus royalties on net sales. ALT-B4 temporarily depolymerizes hyaluronan in the extracellular matrix, enabling co-administered biologics to disperse and absorb subcutaneously rather than requiring intravenous infusion. The transaction is Alteogen's fourth Hybrozyme deal in 2026 following prior agreements with Merck KGaA, Sanofi, and one undisclosed global pharma. The technology approach mirrors Halozyme Therapeutics's ENHANZE platform (used in Roche's SC Herceptin, Rituxan, and Ocrevus, plus Bristol Myers Squibb's SC Opdivo and Johnson & Johnson's SC Darzalex), and the SC-conversion category has become an anchor commercial strategy for pharma companies looking to extend patent life and improve patient convenience on established IV biologics.

#alteogen #196170-kosdaq #novartis #nvs #alt-b4 #berahyaluronidase-alfa #hybrozyme-technology #subcutaneous-conversion #3-22-billion-option-license #hyaluronan-depolymerization #halozyme-enhanze-competitor #iv-to-sc-conversion #non-peptide
Industry

Superluminal Medicines Raises Oversubscribed $60 Million Series B to Advance Selective MC4R Agonist Into Phase 1 for Rare Genetic Obesity and Hypothalamic Obesity

Superluminal Medicines announced Thursday September 3, 2026 an oversubscribed $60 million Series B financing round led by BVF Partners with participation from Deep Track Capital, Perceptive Advisors, RA Capital Management, Insight Partners, NVIDIA, Catalio Capital Management, Eli Lilly and Company, Cooley, and Gaingels. Proceeds will advance the company's lead clinical program (a selective, biased MC4R agonist) into Phase 1 for rare genetic forms of obesity including Bardet-Biedl syndrome (BBS) and hypothalamic obesity, targeting Phase 1 initiation by end of 2026. Superluminal's technology platform uses AI plus GPCR-structural chemistry to design biased agonists with reduced off-target signaling. The MC4R agonist positioning is directly against Rhythm Pharmaceuticals's Imcivree (setmelanotide, the currently-approved MC4R agonist peptide for BBS and hypothalamic obesity) — a small-molecule alternative would have oral bioavailability advantages plus different tolerability profile. Eli Lilly's investor participation extends Lilly's obesity-adjacent equity portfolio.

#superluminal-medicines #60-million-series-b #mc4r-agonist #selective-biased-agonist #rare-genetic-obesity #bardet-biedl-syndrome #hypothalamic-obesity #imcivree-comparator #setmelanotide-comparator #ai-drug-discovery #gpcr-platform #eli-lilly-investor #non-peptide
Industry

QL Biopharm Closes $73 Million Series C to Advance Monthly Zovaglutide GLP-1 Receptor Agonist Through Phase 3 HORIZON-1 Obesity Trial in China

QL Biopharm (Beijing, Zhitai Biopharmaceutical) closed a Series C financing round of over 500 million Chinese yuan (approximately $73 million) led by OrbiMed with participation from Qiming Venture Partners and other investors, per September 3, 2026 disclosure. Proceeds will support continued development of the company's lead candidate zovaglutide (ZT002, a monthly subcutaneous injectable GLP-1 receptor agonist peptide currently in Phase 3 HORIZON-1 trial for weight management in adults with overweight or obesity in China). Phase 2 data at EASD 2025 documented up to 13.8% weight loss at Week 24 with monthly dosing. Zovaglutide is positioned as a potential first-to-market monthly GLP-1 peptide (as opposed to the antibody-peptide conjugate MariTide from Amgen or the lipidated small-molecule approaches at Pfizer/Metsera). The financing extends the H2 2026 obesity-peptide financing wave that has included Parabilis's $670M IPO, Metsera-related asset transitions, and Superluminal's $60M Series B.

#ql-biopharm #zhitai-biopharmaceutical #73-million-series-c #zovaglutide #zt002 #monthly-glp-1-peptide #phase-3-horizon-1 #china-obesity #13-8-percent-weight-loss #orbimed-lead #qiming-venture-partners #monthly-glp-1-race
Industry

Ionis and Royalty Pharma Both Absorb Financial Impact From Novartis Pelacarsen Phase 3 Miss; Program Future Under Review

Ionis Pharmaceuticals (NASDAQ: IONS) and Royalty Pharma (NASDAQ: RPRX) both issued statements Friday September 4, 2026 following the Novartis pelacarsen Lp(a)HORIZON Phase 3 primary endpoint miss. Ionis, the original developer that licensed pelacarsen to Novartis in 2019, is entitled to potential low-double-digit tiered royalties on future net sales that now appear unlikely absent a resubmission based on a different endpoint or population. Royalty Pharma acquired a portion of Ionis's royalty rights on pelacarsen in a 2019 transaction and had modeled multi-hundred-million-dollar revenue on approval. Both companies emphasized the substantial Lp(a) reduction achieved in the trial and the value of the dataset for the broader Lp(a) research field. The miss lands within days of Ionis's September 3 FDA approval of Zanvastro (zilganersen) for Alexander disease, which provided commercial and pipeline offset. Analyst commentary noted that the Ionis antisense franchise remains strong despite the pelacarsen setback, with Wainua (eplontersen), Zanvastro, and the deep pipeline anchoring the platform.

#ionis-pharmaceuticals #ions #royalty-pharma #rprx #pelacarsen #lp-a-horizon-miss #royalty-impact #double-digit-royalties #2019-license #wainua-eplontersen #zanvastro-offset #antisense-franchise
Clinical Trials

Corbus CANYON-1 Phase 1b Topline for CRB-913 Peripherally-Restricted CB1 Inverse Agonist Countdown Enters Final Weeks

Corbus Pharmaceuticals (NASDAQ: CRBP) continued through Saturday September 5, 2026 the countdown to CANYON-1 Phase 1b topline data for CRB-913 (a once-daily orally-administered peripherally-restricted CB1 inverse agonist for obesity). Last patient last visit was announced August 4, 2026, and topline is expected in September 2026 per company Q2 2026 corporate update. The 16-week double-blind placebo-controlled dose-ranging study enrolled 240 obese non-diabetic U.S. adults at once-daily doses of 20 mg, 40 mg, and 60 mg with 4-week safety follow-up. CRB-913 is engineered to remain peripheral (approximately 15-fold lower brain penetration than monlunabant in preclinical models) to preserve efficacy while limiting the psychiatric side effects that led to withdrawal of Sanofi's Acomplia (rimonabant) in 2008. The readout is one of the most-watched non-incretin obesity data points on the September calendar. Clean tolerability plus dose-responsive weight loss would enable Phase 2 initiation and set up CRB-913 as a differentiated add-on or alternative to the GLP-1 class.

#corbus-pharmaceuticals #crbp #crb-913 #canyon-1 #peripherally-restricted-cb1-inverse-agonist #obesity #phase-1b-topline #240-participants #monlunabant-comparator #rimonabant-history #september-2026-readout #non-peptide
Regulatory

FDA Peptide Compounding Regulatory Limbo Enters Seventh Week Since July 23-24 PCAC Vote; No Proposed Rule, No Interim Enforcement Policy

As of Saturday September 5, 2026, the FDA has issued no proposed rule, no Federal Register notice, and no interim enforcement policy following the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) vote to recommend six peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for inclusion on the Section 503A Bulk Drug Substances List. The regulatory silence has now extended six weeks past the vote and continues to leave compounding pharmacies operating in the gray zone that began with the April 16, 2026 removal of 12 peptides from Category 2. Center for Drug Evaluation and Research warning-letter activity to compounding pharmacies has remained elevated through Q3 2026. The February 2027 PCAC meeting to consider cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and pegylated mechano growth factor (PEG-MGF) remains scheduled. Dr. Heidi Overton (nominated FDA Commissioner August 19, 2026) continues to await Senate confirmation with acting Commissioner Kyle Diamantas leading the agency through the interim.

#fda #pcac #503a-bulks-list #bpc-157 #kpv #tb-500 #mots-c #semax #epitalon #compounding-pharmacies #regulatory-limbo-week-seven #warning-letters #february-2027-pcac #overton-nomination-pending
Industry

EASD 2026 Rome September 28 Through October 2 Sets Up September Obesity Peptide Catalyst Calendar Anchored on Amylin Data

The European Association for the Study of Diabetes (EASD) 62nd Annual Meeting takes place in Rome September 28 through October 2, 2026, and sets up the largest single September catalyst window for obesity-peptide investor and clinical interest. AstraZeneca will present Phase 2 data on AZD6234 (selective amylin receptor peptide agonist) monotherapy from APRICUS plus the ASCEND Phase 2b combination with AZD9550 GLP-1/glucagon dual agonist. Zealand Pharma and Roche will present petrelintide (amylin analog) data from ZUPREME-2 (obesity plus type 2 diabetes) with the Phase 3 monotherapy program preparing to initiate late 2026. Novo Nordisk will present amycretin (long-acting GLP-1/amylin dual agonist) plus CagriSema follow-through data. The EASD calendar coincides with the Roche Pharma Day investor event on Monday September 28, 2026 that will update on the top-three-obesity-portfolio (petrelintide, enicepatide, HM17321). Ascendis Pharma is also expected to provide TransCon CNP achondroplasia updates.

#easd-2026 #rome-september-28-october-2 #azd6234 #astrazeneca #petrelintide #zealand-pharma #roche-pharma-day #amycretin #novo-nordisk #cagrisema #enicepatide #hm17321 #amylin-agonist-race #obesity-catalyst-calendar
Clinical Trials

Amgen MariTide Switch Trial Continues Enrollment as Obesity Market Positions for 2027-2028 Monthly Injectable Launch

Amgen (NASDAQ: AMGN) continued enrollment through September 2026 in the dedicated MARITIME switch trial that specifically tests whether patients currently on weekly semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) can be converted to monthly MariTide (maridebart cafraglutide, antibody-peptide conjugate combining GLP-1 receptor agonism with GIP receptor antagonism) with equivalent weight-loss maintenance and comparable tolerability. Filing for FDA approval is planned late 2026 to early 2027 with anticipated launch 2027-2028. Six total Phase 3 MariTide trials are enrolling across obesity (MARITIME-1), obesity plus type 2 diabetes (MARITIME-2), cardiovascular outcomes (MARITIME-CVD), heart failure (MARITIME-HF), obstructive sleep apnea (MARITIME-OSA), plus the switch trial. Cantor Fitzgerald analyst commentary earlier in 2026 had flagged a 4% bone mineral density decline signal from Phase 1 as a factor to watch; Phase 3 data on bone health will affect prescribing guidance especially for adults over 60 or with prior fracture history.

#amgen #amgn #maritide #maridebart-cafraglutide #monthly-injectable #antibody-peptide-conjugate #switch-trial #glp-1-to-maritide #six-phase-3-trials #bone-mineral-density-signal #late-2026-early-2027-filing #obesity-2027-2028